BAP1 exerts its tumor-suppressive effects by inhibiting the JNK/c-Jun pathway, suggesting that the JNK signaling pathway could serve as a potential therapeutic target in ICC (75, 76). This evidence concerns the gene BAP1 and intrahepatic cholangiocarcinoma.